|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.57 CNY | +1.27% |
|
+2.96% | +5.52% |
| 11-21 | Yixintang Pharmaceutical Approves 1.4 Billion Yuan Credit Guarantees | MT |
| 11-14 | Yixintang Pharmaceutical Group Co., Ltd. Announces Board Appointments | CI |
| Capitalization | 7.79B 1.12B 960M 895M 832M 1.55B 101B 1.67B 10.29B 4.04B 48.2B 4.19B 4.1B 178B | P/E ratio 2025 * |
19x | P/E ratio 2026 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise value | 6.28B 900M 774M 721M 670M 1.25B 81.32B 1.35B 8.29B 3.26B 38.86B 3.38B 3.31B 143B | EV / Sales 2025 * |
0.35x | EV / Sales 2026 * | 0.29x |
| Free-Float |
52.87% | Yield 2025 * |
1.78% | Yield 2026 * | 2.21% |
| 1 day | +1.27% | ||
| 1 week | +2.96% | ||
| Current month | +5.52% | ||
| 1 month | +8.04% | ||
| 3 months | -1.24% | ||
| 6 months | -16.29% | ||
| Current year | +5.52% |
| 1 week | 13.09 |  | 13.81 |
| 1 month | 12.43 | | 14.33 |
| Current year | 12.92 | | 13.81 |
| 1 year | 11.81 | | 19.59 |
| 3 years | 10.84 | | 36.39 |
| 5 years | 10.84 | | 50.1 |
| 10 years | 10.84 | | 50.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Hong Xian Ruan
PSD | President | 60 | 24/11/2019 |
Dong Lei Xiao
DFI | Director of Finance/CFO | 44 | 21/11/2023 |
Guo Wei Ruan
PRN | Corporate Officer/Principal | 49 | 24/11/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Hong Xian Ruan
CHM | Chairman | 60 | 31/05/2009 |
Qiong Liu
CHM | Chairman | 61 | 31/05/2009 |
Chun Li Guo
BRD | Director/Board Member | 44 | 15/11/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.27% | +2.96% | +13.08% | -59.21% | 1.12B | |
| +3.34% | +13.25% | +145.25% | +3.34% | 27.73B | |
| +18.96% | +40.18% | +132.93% | +5.85% | 13.55B | |
| -1.22% | -2.17% | +18.72% | +24.40% | 6.55B | |
| -0.25% | +2.74% | -6.15% | +23.01% | 4.95B | |
| +1.91% | +1.36% | -7.36% | -38.97% | 3.9B | |
| +0.91% | +1.39% | -20.77% | -46.00% | 3.25B | |
| -0.05% | +2.72% | +33.50% | -48.52% | 3.03B | |
| +1.16% | -2.53% | -8.44% | +64.42% | 2.87B | |
| -0.79% | -0.06% | +48.64% | - | 1.98B | |
| Average | +2.52% | +3.65% | +34.94% | -7.97% | 6.89B | |
| Weighted average by Cap. | +5.13% | +7.74% | +87.24% | +1.74% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 17.93B 2.57B 2.21B 2.06B 1.91B 3.57B 232B 3.85B 23.68B 9.3B 111B 9.64B 9.44B 409B | 20.4B 2.92B 2.51B 2.34B 2.18B 4.06B 264B 4.38B 26.93B 10.58B 126B 10.96B 10.74B 465B |
| Net income | 418M 59.87M 51.44M 47.97M 44.58M 83.17M 5.41B 89.69M 552M 217M 2.58B 225M 220M 9.53B | 675M 96.75M 83.13M 77.52M 72.04M 134M 8.74B 145M 891M 350M 4.18B 363M 355M 15.4B |
| Net Debt | -1.51B -216M -186M -173M -161M -301M -19.55B -324M -1.99B -783M -9.34B -812M -795M -34.45B | -1.88B -270M -232M -216M -201M -375M -24.38B -404M -2.49B -977M -11.65B -1.01B -991M -42.96B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 13.57 ¥ | +1.27% | 24,314,050 |
| 12/01/26 | 13.40 ¥ | +0.75% | 13,735,940 |
| 09/01/26 | 13.30 ¥ | +0.61% | 10,923,240 |
| 08/01/26 | 13.22 ¥ | +1.07% | 9,540,779 |
| 07/01/26 | 13.08 ¥ | -0.76% | 10,182,960 |
End-of-day quote Shenzhen S.E., January 12, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 002727 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition